HAEM5:Acute basophilic leukaemia - Revision history

Bailey.Glen at 17:06, 3 July 2025

2025-07-03T17:06:02Z

← Older revision		Revision as of 12:06, 3 July 2025
Line 34:		Line 34:
	\|}		\|}

	~~==WHO Essential and Desirable Genetic Diagnostic Criteria==~~
	<span style="color:#0070C0">(''Instructions: The table will have the diagnostic criteria from the WHO book <u>autocompleted</u>; remove any <u>non</u>-genetics related criteria. If applicable, add text about other classification'' ''systems that define this entity and specify how the genetics-related criteria differ.'')</span>
	~~{\| class="wikitable"~~
	\|+
	\|WHO Essential Criteria (Genetics)*
	\|
	\|-
	\|WHO Desirable Criteria (Genetics)*
	\|
	\|-
	~~\|Other Classification~~
	\|
	\|}
	<nowiki>*</nowiki>Note: These are only the genetic/genomic criteria. Additional diagnostic criteria can be found in the [https://tumourclassification.iarc.who.int/home <u>WHO Classification of Tumours</u>].
	==Related Terminology==		==Related Terminology==

Bailey.Glen at 21:25, 25 May 2025

2025-05-25T21:25:25Z

← Older revision		Revision as of 16:25, 25 May 2025
Line 160:		Line 160:
	{\| class="wikitable sortable"		{\| class="wikitable sortable"
	\|-		\|-
	!Chr #!!~~'''~~Gain, Loss, Amp, LOH~~'''~~!!~~'''~~Minimal Region Cytoband and/or Genomic Coordinates [Genome Build; Size]~~'''~~!!~~'''~~Relevant Gene(s)~~'''~~		!Chr #!!Gain, Loss, Amp, LOH!!Minimal Region Cytoband and/or Genomic Coordinates [Genome Build; Size]!!Relevant Gene(s)
	!~~'''~~Diagnostic, Prognostic, and Therapeutic Significance - D, P, T~~'''~~		!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
	!~~'''~~Established Clinical Significance Per Guidelines - Yes or No (Source)~~'''~~		!Established Clinical Significance Per Guidelines - Yes or No (Source)
	!~~'''~~Clinical Relevance Details/Other Notes~~'''~~		!Clinical Relevance Details/Other Notes
	\|-		\|-
	\|<span class="blue-text">EXAMPLE:</span>		\|<span class="blue-text">EXAMPLE:</span>
Line 226:		Line 226:
	!Chromosomal Pattern		!Chromosomal Pattern
	!Molecular Pathogenesis		!Molecular Pathogenesis
	!~~'''~~Prevalence -~~'''~~		!Prevalence -
	~~'''~~Common >20%, Recurrent 5-20% or Rare <5% (Disease)~~'''~~		Common >20%, Recurrent 5-20% or Rare <5% (Disease)
	!~~'''~~Diagnostic, Prognostic, and Therapeutic Significance - D, P, T~~'''~~		!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
	!~~'''~~Established Clinical Significance Per Guidelines - Yes or No (Source)~~'''~~		!Established Clinical Significance Per Guidelines - Yes or No (Source)
	!~~'''~~Clinical Relevance Details/Other Notes~~'''~~		!Clinical Relevance Details/Other Notes
	\|-		\|-
	\|<span class="blue-text">EXAMPLE:</span>		\|<span class="blue-text">EXAMPLE:</span>
Line 270:		Line 270:
	{\| class="wikitable sortable"		{\| class="wikitable sortable"
	\|-		\|-
	!Gene!!~~'''~~Genetic Alteration~~'''~~!!~~'''~~Tumor Suppressor Gene, Oncogene, Other~~'''~~!!~~'''~~Prevalence -~~'''~~		!Gene!!Genetic Alteration!!Tumor Suppressor Gene, Oncogene, Other!!Prevalence -
	~~'''~~Common >20%, Recurrent 5-20% or Rare <5% (Disease)~~'''~~		Common >20%, Recurrent 5-20% or Rare <5% (Disease)
	!~~'''~~Diagnostic, Prognostic, and Therapeutic Significance - D, P, T ~~'''~~		!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
	!~~'''~~Established Clinical Significance Per Guidelines - Yes or No (Source)~~'''~~		!Established Clinical Significance Per Guidelines - Yes or No (Source)
	!~~'''~~Clinical Relevance Details/Other Notes~~'''~~		!Clinical Relevance Details/Other Notes
	\|-		\|-
	\|<span class="blue-text">EXAMPLE:</span>''EGFR''		\|<span class="blue-text">EXAMPLE:</span>''EGFR''

Bailey.Glen at 20:01, 25 May 2025

2025-05-25T20:01:50Z

← Older revision		Revision as of 15:01, 25 May 2025
Line 49:		Line 49:
	<nowiki>*</nowiki>Note: These are only the genetic/genomic criteria. Additional diagnostic criteria can be found in the [https://tumourclassification.iarc.who.int/home <u>WHO Classification of Tumours</u>].		<nowiki>*</nowiki>Note: These are only the genetic/genomic criteria. Additional diagnostic criteria can be found in the [https://tumourclassification.iarc.who.int/home <u>WHO Classification of Tumours</u>].
	==Related Terminology==		==Related Terminology==
	~~<span style="color:#0070C0">(''Instructions: The table will have the related terminology from the WHO <u>autocompleted</u>.)''</span>~~
	{\| class="wikitable"		{\| class="wikitable"
	\|+		\|+
	\|Acceptable		\|Acceptable
	\|		\|N/A
	\|-		\|-
	\|Not Recommended		\|Not Recommended
	\|		\|Basophilic leukaemia
	\|}		\|}

Bailey.Glen at 17:29, 24 March 2025

2025-03-24T17:29:29Z

← Older revision		Revision as of 12:29, 24 March 2025
Line 1:		Line 1:
	{{DISPLAYTITLE:Acute basophilic leukaemia}}		{{DISPLAYTITLE:Acute basophilic leukaemia}}

	[[HAEM5:Table_of_Contents\|Haematolymphoid Tumours (WHO Classification, 5th ed.)]]		[[HAEM5:Table_of_Contents\|Haematolymphoid Tumours (WHO Classification, 5th ed.)]]

Line 13:		Line 12:

	Ashwini Yenamandra PhD FACMG		Ashwini Yenamandra PhD FACMG

	~~__TOC__~~

	==WHO Classification of Disease==		==WHO Classification of Disease==

Bailey.Glen: Removed old template contents

2025-02-11T13:56:24Z

Removed old template contents

Show changes

Bailey.Glen at 18:36, 10 February 2025

2025-02-10T18:36:58Z

Show changes

Bailey.Glen at 18:08, 10 February 2025

2025-02-10T18:08:57Z

← Older revision		Revision as of 13:08, 10 February 2025
Line 69:		Line 69:


	<blockquote class='blockedit'>{{Box-round\|title=v4:Clinical Features\|The content below was from the old template. Please incorporate above.}}		<blockquote class='blockedit'>{{Box-round\|title=v4:Clinical Features\|The content below was from the old template. Please incorporate above.}}</blockquote>

	Clinical features include bone marrow failure and may or may not have circulating blasts. Cutaneous involvement, oraganomegaly, lytic lesions and symptoms related to hyperhistanemia may be present<ref name=":0" />.		Clinical features include bone marrow failure and may or may not have circulating blasts. Cutaneous involvement, oraganomegaly, lytic lesions and symptoms related to hyperhistanemia may be present<ref name=":0" />.

			<blockquote class="blockedit">
			<center><span style="color:Maroon">'''End of V4 Section'''</span>
			----
	</blockquote>		</blockquote>
	==Sites of Involvement==		==Sites of Involvement==
Line 122:		Line 125:


	<blockquote class='blockedit'>{{Box-round\|title=v4:Chromosomal Rearrangements (Gene Fusions)\|The content below was from the old template. Please incorporate above.}}		<blockquote class='blockedit'>{{Box-round\|title=v4:Chromosomal Rearrangements (Gene Fusions)\|The content below was from the old template. Please incorporate above.}}</blockquote>

	No consistent chromosomal abnormalities have been reported in ABL due to its rarity<ref name=":3">Yenamandra A, et al., (2014). Acute basophilic leukemia, a rare subset of de novo AML with an abnormal tetraploid karyotype. JSM Cell Dev Biol 2(1):1007. Available online at <nowiki>https://www.academia.edu/28924195/Editorial_Article_Acute_Basophilic_Leukemia_a_Rare_Subset_of_De_Novo_AML_with_an_Abnormal_Tetraploid_Karyotype</nowiki>.</ref><ref name=":4">{{Cite journal\|last=Dastugue\|first=N.\|last2=Duchayne\|first2=E.\|last3=Kuhlein\|first3=E.\|last4=Rubie\|first4=H.\|last5=Demur\|first5=C.\|last6=Aurich\|first6=J.\|last7=Robert\|first7=A.\|last8=Sie\|first8=P.\|date=1997\|title=Acute basophilic leukaemia and translocation t(X;6)(p11;q23)\|url=https://www.ncbi.nlm.nih.gov/pubmed/9233581\|journal=British Journal of Haematology\|volume=98\|issue=1\|pages=170–176\|doi=10.1046/j.1365-2141.1997.1562968.x\|issn=0007-1048\|pmid=9233581}}</ref><ref name=":5">{{Cite journal\|last=Quelen\|first=Cathy\|last2=Lippert\|first2=Eric\|last3=Struski\|first3=Stephanie\|last4=Demur\|first4=Cécile\|last5=Soler\|first5=Gwendoline\|last6=Prade\|first6=Nais\|last7=Delabesse\|first7=Eric\|last8=Broccardo\|first8=Cyril\|last9=Dastugue\|first9=Nicole\|date=2011\|title=Identification of a transforming MYB-GATA1 fusion gene in acute basophilic leukemia: a new entity in male infants\|url=https://www.ncbi.nlm.nih.gov/pubmed/21474671\|journal=Blood\|volume=117\|issue=21\|pages=5719–5722\|doi=10.1182/blood-2011-01-333013\|issn=1528-0020\|pmid=21474671}}</ref>. Rearrangement of MYB/GATA1 with t(X;6)(p11;q23) has been reported in four male infants<ref name=":4" /><ref name=":5" />. The fusion gene leads to downregulation of ''MYB'', upregulation of ''GATA1'', and commits myeloid cells to the granulocyte lineage and blocks their differentiation<ref name=":4" /><ref name=":5" />.		No consistent chromosomal abnormalities have been reported in ABL due to its rarity<ref name=":3">Yenamandra A, et al., (2014). Acute basophilic leukemia, a rare subset of de novo AML with an abnormal tetraploid karyotype. JSM Cell Dev Biol 2(1):1007. Available online at <nowiki>https://www.academia.edu/28924195/Editorial_Article_Acute_Basophilic_Leukemia_a_Rare_Subset_of_De_Novo_AML_with_an_Abnormal_Tetraploid_Karyotype</nowiki>.</ref><ref name=":4">{{Cite journal\|last=Dastugue\|first=N.\|last2=Duchayne\|first2=E.\|last3=Kuhlein\|first3=E.\|last4=Rubie\|first4=H.\|last5=Demur\|first5=C.\|last6=Aurich\|first6=J.\|last7=Robert\|first7=A.\|last8=Sie\|first8=P.\|date=1997\|title=Acute basophilic leukaemia and translocation t(X;6)(p11;q23)\|url=https://www.ncbi.nlm.nih.gov/pubmed/9233581\|journal=British Journal of Haematology\|volume=98\|issue=1\|pages=170–176\|doi=10.1046/j.1365-2141.1997.1562968.x\|issn=0007-1048\|pmid=9233581}}</ref><ref name=":5">{{Cite journal\|last=Quelen\|first=Cathy\|last2=Lippert\|first2=Eric\|last3=Struski\|first3=Stephanie\|last4=Demur\|first4=Cécile\|last5=Soler\|first5=Gwendoline\|last6=Prade\|first6=Nais\|last7=Delabesse\|first7=Eric\|last8=Broccardo\|first8=Cyril\|last9=Dastugue\|first9=Nicole\|date=2011\|title=Identification of a transforming MYB-GATA1 fusion gene in acute basophilic leukemia: a new entity in male infants\|url=https://www.ncbi.nlm.nih.gov/pubmed/21474671\|journal=Blood\|volume=117\|issue=21\|pages=5719–5722\|doi=10.1182/blood-2011-01-333013\|issn=1528-0020\|pmid=21474671}}</ref>. Rearrangement of MYB/GATA1 with t(X;6)(p11;q23) has been reported in four male infants<ref name=":4" /><ref name=":5" />. The fusion gene leads to downregulation of ''MYB'', upregulation of ''GATA1'', and commits myeloid cells to the granulocyte lineage and blocks their differentiation<ref name=":4" /><ref name=":5" />.
Line 134:		Line 137:
	\|}		\|}

			<blockquote class="blockedit">
			<center><span style="color:Maroon">'''End of V4 Section'''</span>
			----
	</blockquote>		</blockquote>

Line 141:		Line 147:
	* Individual Region Genomic Gain/Loss/LOH		* Individual Region Genomic Gain/Loss/LOH
	* Characteristic Chromosomal Patterns		* Characteristic Chromosomal Patterns
	* Gene Mutations (SNV/INDEL)}}		* Gene Mutations (SNV/INDEL)}}</blockquote>

	Diagnosis of this disease may allow for appropriate prophylactic measures, including H1 and H2 blockers and proton pump inhibitors and steroids, to be initiated in an attempt to minimize its protean complications<ref name=":0" />.		Diagnosis of this disease may allow for appropriate prophylactic measures, including H1 and H2 blockers and proton pump inhibitors and steroids, to be initiated in an attempt to minimize its protean complications<ref name=":0" />.
Line 147:		Line 153:
	This disease is prognostically unfavorable and may have unique therapeutic complications, including anaphylaxis and life threatening cardiac involvement. A low remission rate and short survival are characteristic of ABL<ref name=":0" /><ref name=":3" /><ref name=":4" />.		This disease is prognostically unfavorable and may have unique therapeutic complications, including anaphylaxis and life threatening cardiac involvement. A low remission rate and short survival are characteristic of ABL<ref name=":0" /><ref name=":3" /><ref name=":4" />.

			<blockquote class="blockedit">
			<center><span style="color:Maroon">'''End of V4 Section'''</span>
			----
	</blockquote>		</blockquote>
	==Individual Region Genomic Gain / Loss / LOH==		==Individual Region Genomic Gain / Loss / LOH==
Line 195:		Line 204:
	\|}		\|}

	<blockquote class='blockedit'>{{Box-round\|title=v4:Genomic Gain/Loss/LOH\|The content below was from the old template. Please incorporate above.}}		<blockquote class='blockedit'>{{Box-round\|title=v4:Genomic Gain/Loss/LOH\|The content below was from the old template. Please incorporate above.}}</blockquote>

	Not applicable.		Not applicable.

			<blockquote class="blockedit">
			<center><span style="color:Maroon">'''End of V4 Section'''</span>
			----
	</blockquote>		</blockquote>
	==Characteristic Chromosomal Patterns==		==Characteristic Chromosomal Patterns==
Line 223:		Line 235:
	\|}		\|}

	<blockquote class='blockedit'>{{Box-round\|title=v4:Characteristic Chromosomal Aberrations / Patterns\|The content below was from the old template. Please incorporate above.}}		<blockquote class='blockedit'>{{Box-round\|title=v4:Characteristic Chromosomal Aberrations / Patterns\|The content below was from the old template. Please incorporate above.}}</blockquote>

	A few male patients have been reported with massive hyperdiploid or tetraploid karyotypes<ref name=":1" /><ref name=":2" /><ref name=":3" /><ref>{{Cite journal\|last=Kim\|first=Bo Hyun\|last2=Kim\|first2=Hye Ryoun\|last3=Lee\|first3=Mi-Kyung\|last4=Chi\|first4=Hyunyoung\|date=2013\|title=Two cases of near-tetraploidy in acute leukemias of ambiguous lineage\|url=https://www.ncbi.nlm.nih.gov/pubmed/24003431\|journal=Annals of Laboratory Medicine\|volume=33\|issue=5\|pages=371–374\|doi=10.3343/alm.2013.33.5.371\|issn=2234-3814\|pmc=3756245\|pmid=24003431}}</ref>. Monosomy 7 was reported in a rare case<ref>{{Cite journal\|last=Shin\|first=So Youn\|last2=Koo\|first2=Sun Hoe\|last3=Kwon\|first3=Kye Cheol\|last4=Park\|first4=Jong Woo\|last5=Ko\|first5=Chi Seon\|last6=Jo\|first6=Deog Yeon\|date=2007\|title=Monosomy 7 as the sole abnormality of an acute basophilic leukemia\|url=https://www.ncbi.nlm.nih.gov/pubmed/17213028\|journal=Cancer Genetics and Cytogenetics\|volume=172\|issue=2\|pages=168–171\|doi=10.1016/j.cancergencyto.2006.09.016\|issn=0165-4608\|pmid=17213028}}</ref>.		A few male patients have been reported with massive hyperdiploid or tetraploid karyotypes<ref name=":1" /><ref name=":2" /><ref name=":3" /><ref>{{Cite journal\|last=Kim\|first=Bo Hyun\|last2=Kim\|first2=Hye Ryoun\|last3=Lee\|first3=Mi-Kyung\|last4=Chi\|first4=Hyunyoung\|date=2013\|title=Two cases of near-tetraploidy in acute leukemias of ambiguous lineage\|url=https://www.ncbi.nlm.nih.gov/pubmed/24003431\|journal=Annals of Laboratory Medicine\|volume=33\|issue=5\|pages=371–374\|doi=10.3343/alm.2013.33.5.371\|issn=2234-3814\|pmc=3756245\|pmid=24003431}}</ref>. Monosomy 7 was reported in a rare case<ref>{{Cite journal\|last=Shin\|first=So Youn\|last2=Koo\|first2=Sun Hoe\|last3=Kwon\|first3=Kye Cheol\|last4=Park\|first4=Jong Woo\|last5=Ko\|first5=Chi Seon\|last6=Jo\|first6=Deog Yeon\|date=2007\|title=Monosomy 7 as the sole abnormality of an acute basophilic leukemia\|url=https://www.ncbi.nlm.nih.gov/pubmed/17213028\|journal=Cancer Genetics and Cytogenetics\|volume=172\|issue=2\|pages=168–171\|doi=10.1016/j.cancergencyto.2006.09.016\|issn=0165-4608\|pmid=17213028}}</ref>.

			<blockquote class="blockedit">
			<center><span style="color:Maroon">'''End of V4 Section'''</span>
			----
	</blockquote>		</blockquote>
	==Gene Mutations (SNV / INDEL)==		==Gene Mutations (SNV / INDEL)==
Line 262:		Line 277:


	<blockquote class='blockedit'>{{Box-round\|title=v4:Gene Mutations (SNV/INDEL)\|The content below was from the old template. Please incorporate above.}}		<blockquote class='blockedit'>{{Box-round\|title=v4:Gene Mutations (SNV/INDEL)\|The content below was from the old template. Please incorporate above.}}</blockquote>

	Not applicable.		Not applicable.
Line 270:		Line 285:
	Not applicable.		Not applicable.

			<blockquote class="blockedit">
			<center><span style="color:Maroon">'''End of V4 Section'''</span>
			----
	</blockquote>		</blockquote>
	==Epigenomic Alterations==		==Epigenomic Alterations==
Line 295:		Line 313:
	\|}		\|}

	<blockquote class='blockedit'>{{Box-round\|title=v4:Genes and Main Pathways Involved\|The content below was from the old template. Please incorporate above.}}		<blockquote class='blockedit'>{{Box-round\|title=v4:Genes and Main Pathways Involved\|The content below was from the old template. Please incorporate above.}}</blockquote>

	The molecular mechanism is not completely understood.		The molecular mechanism is not completely understood.

			<blockquote class="blockedit">
			<center><span style="color:Maroon">'''End of V4 Section'''</span>
			----
	</blockquote>		</blockquote>
	==Genetic Diagnostic Testing Methods==		==Genetic Diagnostic Testing Methods==

Bailey.Glen at 22:20, 6 September 2024

2024-09-06T22:20:23Z

← Older revision		Revision as of 17:20, 6 September 2024
Line 15:		Line 15:
	__TOC__		__TOC__

	==~~Cancer Category / Type~~==		==WHO Classification of Disease==

	~~[[AML~~\|~~Acute~~ Myeloid ~~Leukemia]]~~		{\| class="wikitable"
			!Structure
	~~==Cancer Sub~~-~~Classification / Subtype==~~		!Disease
			\|-
	Acute ~~Basophilic Leukemia~~ (~~ABL~~)		\|Book
			\|Haematolymphoid Tumours (5th ed.)
			\|-
			\|Category
			\|Myeloid proliferations and neoplasms
			\|-
			\|Family
			\|Acute myeloid leukaemia
			\|-
			\|Type
			\|Acute myeloid leukaemia, defined by differentiation
			\|-
			\|Subtype(s)
			\|Acute basophilic leukaemia
			\|}

	==Definition / Description of Disease==		==Definition / Description of Disease==

Bailey.Glen at 21:47, 6 September 2024

2024-09-06T21:47:29Z

Show changes

Bailey.Glen: Undo revision 14799 by Bailey.Glen (talk)

2024-09-06T19:51:38Z

Undo revision 14799 by Bailey.Glen (talk)

Show changes